Bonac Corporation (“Bonac”; HQ: Kurume City, Fukuoka; CEO: Hirotake Hayashi) together with a research group led by Professor Tadatsugu Taniguchi at the University of Tokyo's Division of Inflammation and Immunoregulation established by Kyowa Kirin Co., Ltd., announce a publication of Dectin-1, one of the innate immune receptors expressed on macrophages and dendritic cells, directly recognizes cancer cells and activates the innate immune system. As a result, cancer cells are eliminated from the body.

 

The research results were published in the journal "eLife (https://elifesciences.org/content/3/e04177)" on August 22, 2014.

 

This research result is the world's first clarification that innate immune receptors recognize cancer cells and promote their elimination.

 

It is expected that this research will lead to the development of new cancer treatment and prevention methods through the activation of the innate immune system.

 

Bonac is determined to develop innovative nucleic acid drugs by utilizing the results produced by the collaboration, and will continue to promote research and development so that the nucleic acid technology will serve as a bridge to drug discovery.

 

Contact:

Corporate Affairs

press@bonac.co.jp